RWLK REWALK ROBOTICS LTD

ReWalk Robotics to Present at the H.C. WAINWRIGHT 22nd Annual Global Investment Virtual Conference on September 15th, 2020

ReWalk Robotics to Present at the H.C. WAINWRIGHT 22nd Annual Global Investment Virtual Conference on September 15th, 2020

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer, Ori Gon, Chief Financial Officer and Andy Dolan, VP Marketing and Reimbursement, will present at the H.C. WAINWRIGHT virtual conference at 11:00 EST on Tuesday, September 15, 2020.

A live and archived webcast of the presentation will be available on the investor section of the company’s website at: 

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.  ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.

Contact:

Ori Gon

Chief Financial Officer 

ReWalk Robotics Ltd.

T:  

E: 

EN
10/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Successfully Closes on Strategic Partnership with Oramed HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear...

 PRESS RELEASE

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Lt...

 PRESS RELEASE

Lifeward Receives Shareholder Approval to Close on Strategic Partnersh...

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform’s clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovati...

 PRESS RELEASE

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule"). To regain compliance with the...

 PRESS RELEASE

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results...

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch